This is a routine governance filing with no immediate financial impact. Monitor the next quarterly report for any changes in audit findings or financial reporting quality under KPMG. The renewed share issuance and buyback authorizations are standard and do not signal imminent capital actions.
PHAR drugs
PHAR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 28 $13.66entry
- T+1 · 6mo ago −4.90%α −5.14% · $12.99
- T+5 · 6mo ago −10.40%α −10.35% · $12.24
- T+20 · 5mo ago −2.34%α +0.80% · $13.34
- T+60 · 3mo ago −13.25%α −14.99% · $11.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharming Group N.V. filed a 6-K reporting the results of its 2026 Annual General Meeting of Shareholders, where shareholders approved all proposals including the appointment of KPMG Accountants N.V. as the new external auditor for 2026-2028, replacing Deloitte. The filing also notes the renewal of authorizations for the Board to issue and repurchase shares. No financial results or material operational updates were disclosed.
Key Facts
- Shareholders approved all AGM proposals on May 28, 2026.
- KPMG Accountants N.V. appointed as external auditor for fiscal years 2026-2028, replacing Deloitte.
- Deloitte's reports for 2024 and 2025 contained no adverse opinion or disclaimer of opinion.
- No disagreements or reportable events occurred between the company and Deloitte during the relevant periods, except for previously disclosed material weaknesses in internal control over financial reporting.
- Authorizations for the Board to issue shares and repurchase shares were renewed.
- Remuneration policy for Non-Executive Directors' fees was amended.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Auditor change may lead to adjustments in financial reporting processes or internal controls.
- Previously disclosed material weaknesses in internal control over financial reporting remain unresolved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000029 |
| Document: 0001828316-26-000029-index-headers.html | 0001828316-26-000029 |
| Document: 0001828316-26-000029-index.html | 0001828316-26-000029 |
| Document: 0001828316-26-000029.txt | 0001828316-26-000029 |
Track record
18 reports on PHAR
9 of 15 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 11 of 15 went positive at some point.
Filters
- Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Oct 27, 202620d ago 6-K Bullish 6/10 No price data
- Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
- Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
- Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
- Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers